A retrospective cohort study analyzed the weight loss effects of semaglutide in postmenopausal women using hormone therapy. Postmenopausal women on hormone therapy experienced greater weight loss with semaglutide compared to non-users. At various intervals, hormone therapy users consistently lost more weight and achieved clinically significant weight loss thresholds. Both groups showed improvements in cardiometabolic markers, with greater reductions in total cholesterol and triglycerides observed in hormone therapy users. Study investigators noted the importance of interventions to prevent weight gain and manage overweight and obesity in postmenopausal women, highlighting the potential significance for cardiovascular disease prevention.

Source: Menopause: The Journal of The Menopause Society